We'll soon be changing our name to Action FCS. Look out for our new and improved website.
menu

Volanesorsen and Triglyceride Levels in Familial Chylomicronaemia Syndrome

Published results from the Phase 3 APPROACH study evaluating WAYLIVRA® (Volanesorsen) in patients with familial chylomicronaemia syndrome (FCS) from the August 9th 2019 issue of The New England Journal of Medicine (NEJM) are available here.    

Published results from the Phase 3 APPROACH study evaluating WAYLIVRA® (Volanesorsen) in patients with familial chylomicronaemia syndrome (FCS) from the August 9th 2019 issue of The New England Journal of Medicine (NEJM) are available here.